Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets |
|
| Acetaminophen 250 mg and aspirin 250 mg | Experimental | 2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acetaminophen 250 mg and Aspirin 250 mg | Drug | 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects Who Are Pain Free at the 2-hour Assessment | Number of subjects who are pain free at the 2-hour assessment | 2 hours |
| Number of Subjects Who Are Nausea Free at the 2-hour Assessment | Number of subjects who are nausea free at the 2-hour assessment | 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment. | Number of subjects who are free of photophobia at the 2-hour assessment. | 2 hours |
| Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment. |
Not provided
Inclusion criteria:
Exclusion criteria:
Subjects eligible for inclusion in this study must not fulfill any of the following criteria:
Headache symptoms which may be due to or aggravated by:
History of vomiting during more than 20% of migraine attacks.
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Project Lead | Novartis Consumer Health | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Birmingham | Alabama | United States | ||||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets Placebo: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets |
| FG001 | Acetaminophen 250 mg and Aspirin 250 mg |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets |
|
Number of subjects who are free of phonophobia at the 2-hour assessment.
| 2 hours |
| Anaheim |
| California |
| United States |
| San Francisco | California | United States |
| Fort Lauderdale | Florida | United States |
| Jupiter | Florida | United States |
| Oviedo | Florida | United States |
| West Palm Beach | Florida | United States |
| Evansville | Indiana | United States |
| Ann Arbor | Michigan | United States |
| Berlin | New Jersey | United States |
| Rochester | New York | United States |
| The Bronx | New York | United States |
| Williamsville | New York | United States |
| Raleigh | North Carolina | United States |
| Cincinnati | Ohio | United States |
| Cleveland | Ohio | United States |
| Mt. Pleasant | South Carolina | United States |
| Salt Lake City | Utah | United States |
| Kenosha | Wisconsin | United States |
2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
Acetaminophen 250 mg and Aspirin 250 mg: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets Placebo: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets |
| BG001 | Acetaminophen 250 mg and Aspirin 250 mg | 2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg Acetaminophen 250 mg and Aspirin 250 mg: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects Who Are Pain Free at the 2-hour Assessment | Number of subjects who are pain free at the 2-hour assessment | Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N = 415) and had a non-missing pain free status at 2 hours (AA: N=408, Placebo: N = 415). | Posted | Number | participants | 2 hours |
|
|
| |||||||||||||||||||||||||||||
| Primary | Number of Subjects Who Are Nausea Free at the 2-hour Assessment | Number of subjects who are nausea free at the 2-hour assessment | Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N=415) and had a non-missing nausea free status at 2 hours (AA: N=403, Placebo N= 411). | Posted | Number | participants | 2 hours |
|
| ||||||||||||||||||||||||||||||
| Secondary | Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment. | Number of subjects who are free of photophobia at the 2-hour assessment. | Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N = 415) and had a non-missing photophobia free status at 2 hours (AA: N=403, Placebo: N = 411). | Posted | Number | participants | 2 hours |
|
| ||||||||||||||||||||||||||||||
| Secondary | Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment. | Number of subjects who are free of phonophobia at the 2-hour assessment. | Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N = 415) and had a non-missing phonophobia free status at 2 hours (AA: N=403, Placebo: N = 411). | Posted | Number | participants | 2 hours |
|
|
Not provided
Number of participants analyzed includes only subjects who treated a migraine (AA: N=408, Placebo: N = 415)
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets Placebo: 2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets | 0 | 415 | 0 | 415 | ||
| EG001 | Acetaminophen 250 mg and Aspirin 250 mg | 2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg Acetaminophen 250 mg and Aspirin 250 mg: 2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg | 1 | 408 | 0 | 408 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| intraductal profilerative breast lesion | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
Not provided
Sponsor shall review results communications prior to public release to evaluate the manuscript for accuracy, ascertain whether information (other than the results of the Clinical Trial) is being improperly disclosed, provided information which may have not have yet been made available by the Sponsor, provide input for consideration regarding the content and/or conclusion(s) of the manuscript and determine whether the manuscript discloses any potentially patentable invention(s).
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Project Leader | Novartis | 9735038000 |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|